Pembrolizumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Pembrolizumab and local guidelines before prescribing.

Immune checkpoint inhibitor

Mechanism

PD-1 inhibitor restoring T-cell antitumour activity.

Uses

Melanoma, non-small-cell lung cancer, head and neck, urothelial and other cancers.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Immune-related colitis, pneumonitis, hepatitis, endocrinopathies, rash, fatigue.

Interactions

Immunosuppressants reduce effect.

Contraindications and cautions

Autoimmune disease caution

Monitoring

TFT, LFT, cortisol, glucose, U&E

Pregnancy and breastfeeding

Avoid; contraception during and after

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive; steroids for immune toxicity

Special advice

Same immune-related toxicity pathway as other checkpoint inhibitors; check TFT and cortisol; steroids early for moderate toxicity.

More from the textbook: uses, cautions and other points
Where it is discussed in the book